HSP90B1 and neoplasm: The identification of a specific tumor antigen is the prerequisite for developing a vaccine to use against that tumor, and a great deal of effort has been made to develop therapeutic vaccines, including those based on Grp94 as either subsidiary or alternative therapeutic option to the chemotherapeutic agents for the cure of different tumors [8, 20, 23, 24].